Assessment of the Phenolics Content in Epilobium angustifolium and Epilobium hirsutum Extracts and Their Pharmacological Activity
- PMID: 40359335
- DOI: 10.1002/ardp.202400765
Assessment of the Phenolics Content in Epilobium angustifolium and Epilobium hirsutum Extracts and Their Pharmacological Activity
Abstract
The recent outbreak of Omicron strains of coronavirus disease urged the search for novel treatments from natural products such as Epilobium species. The present work reports a comparative HPLC-DAD study of the polyphenolic composition of the crude extracts of Epilobium angustifolium and Epilobium hirsutum. Oenothein B, gallic acid, hyperoside, and isoquercitin were the dominant phenolic compounds. E. hirsutum methanol extract showed a high radical scavenging activity as demonstrated by the HPLC-ABTS assay due to its richness in phenolic compounds. The polysaccharide-rich extracts and water extracts of E. hirsutum showed potent anti-coronavirus SARS-CoV-2 activity against the Omicron strain at 10 μg/mL with inhibition percentages of 38.4% and 46.1%, respectively. In contrast, the methanol (50% v/v) extract was inactive. Rutin and chlorogenic acid docked well into the binding pocket of the coronavirus spike protein. Emerging evidence suggests that suppressing excessive neutrophilic inflammation during the late stage of coronavirus infection benefits patients' survival. The methanol extracts of both plants completely inhibited fMLF/CB-induced elastase release in human neutrophils at 10 μg/mL (IC50 2.44 μg/mL), while the water extract showed an IC50 of 5.67 μg/mL. While several compounds docked well into the spike protein, the major and marker compound oenothein B showed promising in vitro anti-coronavirus activity with an IC50 of 6.08 µM in hACE2-overexpressing HEK293 cells, mimicking the entry of wild-type SARS-CoV-2 into human host cells. The results indicated that E. hirsutum might be helpful in the treatment of coronavirus infections and related inflammatory syndromes.
Keywords: Epilobium angustifolium; Epilobium hirsutum; Omicron; neutrophilic inflammation; polyphenolics.
© 2025 Deutsche Pharmazeutische Gesellschaft.
References
-
- R. Sõukand, G. Mattalia, V. Kolosova, et al., “Inventing a Herbal Tradition: The Complex Roots of the Current Popularity of Epilobium angustifolium in Eastern Europe,” Journal of Ethnopharmacology 247 (2020): 112254.
-
- A. Vitalone and O. Allkanjari, “Epilobium spp: Pharmacology and Phytochemistry,” Phytotherapy Research 32, no. 7 (2018): 1229–1240.
-
- EMA/HMPC/712510/2014, Assessment report on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba, European Medicines Agency, Committee on Herbal Medicinal Products (HMPC), 2016; p 20. accessed October 15, 2024, https://www.scribd.com/document/524645489/epilobium-parviflorum-schreb-h....
-
- R. Kalle, O. Belichenko, N. Kuznetsova, et al., “Gaining Momentum: Popularization of Epilobium angustifolium as Food and Recreational Tea on the Eastern Edge of Europe,” Appetite 150 (2020): 104638.
-
- V. Volochai, V. Denesenko, O. Chabovska, et al., “The Study of Growth Conditions of Epilobium angustifolium L. (Onagraceae Juss.) in Natural Populations on the Territory of Ukraine,” Agroecology Journal 1 (2020): 166–172.